The main cause of myocardial infarction, often known as a heart attack, is coronary artery disease, which results in a decreased blood flow to the heart muscles.
Around 17.3 million people worldwide pass away from heart disease each year, with myocardial infarction being the main cause of death, according to the American Heart Association (AHA). According to the British Heart Foundation, coronary heart disease was to blame for 73,680 deaths in the UK in 2012.
If the patient has immediate access to care, the mortality rate from acute myocardial infarction can be reduced.
The market for cardiovascular treatments worldwide brought in 170 billion dollars in 2010 and is predicted to grow significantly between 2016 and 2026.
Download Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1263
Zorprin, Plavix, Angiomax, and a host of other medications are all available for the treatment of acute myocardial infarction with various indications.
Myocardial Infarction Therapeutics Market: Drivers and Restraints
Increasing incidence of coronary artery disease and changes in lifestyle are the major factors expected to drive the growth of global myocardial infarction therapeutics market.
Increasing number of smokers, increasing incidence of obesity and blood pressures, lack of exercise can be some other reasons likely to flourish the global myocardial infarction therapeutics market over the forecast period of 2016-2026.
WHO findings show that the death rate due to cardiovascular diseases is more in smokers than that in non-smokers. Whereas, saturation in R&D can be the major restraint for the growth of global myocardial infarction therapeutics market.
Myocardial Infarction Therapeutics Market: Overview
Analgesics and antiplatelet agents’ segments are foreseen to hold more share in global myocardial infarction therapeutics market as these agents are used for initial treatment of an acute myocardial infarction.
Amongst sales channels, hospital pharmacy segment is expected to contribute more into global myocardial infarction therapeutics market.
The global myocardial infarction therapeutics market is foreseen to experience the boost in market volume over the forecast period due to the launch of several new products such as Apixaban, Xarelto and introduction of generic drugs after expiration of patents for Crestor and Benicar.
Request for Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1263
Myocardial Infarction Therapeutics Market: Regional Overview
Geographically, the global myocardial infarction terapeutic market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.
North America will continue to take leading position in global myocardial infarction therapeutic market owing to expanding aging population and prevalence of co-morbidities.
The expiry of blockbuster drugs in European market is likely to deter the segment share in global myocardial infarction therapeutics market. Japan is expected to experience the stagnancy in global myocardial infarction therapeutics market, in part due to saturation in R&D.
Myocardial Infarction Therapeutics Market: Key Players
Some of the key players in global myocardial infarction therapeutics market are Novartis N.V., Daiichi Sankyo Company Limited, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, AstraZeneca, Apotex Inc., Sandoz, Par Pharmaceutical Companies, Inc., Mylan N.V., Pfizer Inc.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
- Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
- Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
- Japan
- Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.
The report also maps the qualitative impact of various market factors on market segments and geographies.
Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-1263
Myocardial Infarction Therapeutics Market: Segmentation
The global myocardial infarction therapeutics market has been classified on the basis product type, distribution channel and geography.
Based on product type, the global myocardial infarction therapeutics market is divided into following:
- Analgesics
- Antiplatelet agents
- Vasodilators
- Thrombolytics and anti-thrombotic agents
- Glycoprotein IIb/IIIa inhibitors
- Β adrenergic blockers
- Angiotensin receptor antagonists
- Angiotensin converting enzyme inhibitors
Top Related Reports Healthcare Market Insights
https://www.directoryrail.com/preview-directory/
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs